Aplastic anemias and viral hepatitides (posthepatitis aplastic anemias)

Aim. To validate up-to-date policy of immunosuppressive therapy of patients with aplastic anemia (AA) which has developed either at acute or chronic p hase of viral hepatitis. Materials mid methods. 16 patients with AA detected within 6 months (9 pati ents) or 12-36 months (7 patients) after acute viral hepatitis received imm unosuppressive therapy (antilymphocytic globulin, cyclosporin A, splenectom y). Results. Posthepatitis aplastic anemias ran a severe and treatment-resistan t course in most cases. The immunosuppressive therapy produced a response i n 44% of the patients. AA following acute viral hepatitis demands intensive and long-term immunosuppressive therapy with antilymphocytic globulin, cyc losporin A, splenectomy (in some cases) to achieve a persistent clinicohema tological remission.